Compare Emerson Electric Co. (EMR) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Emerson Electric Co. vs GSK plc — how do they compare? Emerson Electric Co. trades at $161.83 (market cap $88.72B), while GSK plc trades at $46.5 (market cap $91.88B). The key difference: Emerson Electric Co. and GSK plc are close in size by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold Emerson Electric Co. for 81 Days and GSK plc for 93 Days on average.
| EMR | GSK | |
|---|---|---|
Market Cap | $88.72B | $91.88B |
Volume | 2,355,255 | 7,730,529 |
Sector | Industrials | Health |
52-Week High | $164.38 | $61.18 |
52-Week Low | $123.30 | $43.24 |
Typical Hold Time | 81 Days | 93 Days |
Enterprise Value | $99.80B | $111.88B |
Dividend Yield | 1.4% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Emerson Electric (EMR) trades at $159.06, down 0.1% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $165.90. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.84. Strong profitability is evident with a 53.16% gross margin and 13.83% net income margin, though valuation multiples like a P/E of 34.81 appear elevated. Recent news highlights momentum and Wall Street optimism.
EMR presents a favorable outlook with earnings momentum and analyst support, but risks include high valuation sensitivity and debt level increases. The stock offers potential upside to the price target, balanced by execution risks in a competitive industrial sector. Investors should weigh solid fundamentals against premium pricing.
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
